A case report of benign metastasizing leiomyoma of the lung: FDG-PET-CT findings and the utility of uterine needle biopsy

Benign metastasizing leiomyoma (BML) is a rare condition that affects other organs out of the uterus. Recently, a few case reports in which 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been used to distinguish the malignancy have been published. Here, the authors present a case of BML with metabolic activity on PET, in which needle biopsy of the uterus was efficient to make diagnosis

Benign metastasizing leiomyoma; FDG-PET-CT; Needle biopsy.

[1] Hellwig D., Baum R.P., Kirsch C.: “FDP-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of the lung cancer: a systematic review”. Nuklear Medizin, 2009, 48, 59.

[2] Cloran F.J., Banks K.P., Song W.S., Kim Y., Bradley Y.C.: “Limitations, of dual time point PET in the assessment of lung nodules with low FDG avidity”. Lung Cancer, 2010, 68, 66.

[3] Lowe V.J., Fletcher J.W., Gobar L., Lawson M., Kirchner P., Valk P., et al.: “Prospective investigation of positron emission tomography in lung nodules”. J. Clin. Oncol., 1998, 16, 1075.

[4] di Scioscio V., Feraco P., Miglio L., Toni F., Malvi D., Pacilli A.M., et al.: “Benign metastasizing leiomyoma of the lung: PET findings”. J. Thorac. Imaging, 2009, 24, 41.

[5] Lin X., Fan W., Lang P., Hu Y., Zhang X., Sun X.: “Benign metastasizing leiomyoma identified using 18F-FDG PET/CT”. Int. J. Gynaecol. Obstet., 2010, 110, 154.

[6] Nakajo M., Nakayama H., Sato M., Fukukura Y., Nakajo M., Kajiya Y., et al.: “FDG-PET/CT finding of benign metastasizing leiomyoma of the lung”. Acta Radiol. Short Rep., 2012, 23, 1.

[7] Shida M., Murakami M., Tsukada H., Ishiguro Y., Kikuchi K., Yamashita E., et al.: “F-18 fluorodeoxyglucose uptake in leiomyomatous uterus”. Int. J. Gynecol. Cancer, 2007, 17, 285.

[8] Chura J.C., Truskinovsky A.M., Judson P.L., Johnson L., Geller M.A., Downs L.S. Jr.: “Positron emission tomography and leiomyomas: clinicopathologic analysis of 3 cases of PETscan-positive leiomyomas and literature review”. Gynecol. Oncol., 2007, 104, 247.

[9] Vriens D., de Geus-Oei L.F., Flucke U.E., van der Kogel A.J., Oyen W.J., Vierhout M.E., et al.: “Benign uterine uptake of FDG: a case report and review of literature”. Neth. J. Med., 2010, 68, 379.

[10] Nishizawa S., Inubushi M., Kido A., Miyagawa M., Inoue T., Shinohara K., Kajihara M.: “Incidence and characteristics of uterine leiomyomas with FDG uptake”. Ann. Nucl. Med., 2008, 22, 803.

[11] Kitajima K., Murakami K., Yamasaki E., Kaji Y., Sugimura K.:“Standardized uptake values of uterine leiomyoma with 18FFDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI”. Ann. Nucl. Med., 2008, 22, 505.

[12] Tsujikawa T., Yoshida Y., Mori T., Kurokawa T., Fujibayashi Y., Kotsuji F., Okazawa H.: “Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucosePET--initial experience”. Radiology, 2008, 248, 599.

[13] Kawamura N., Ichimura T., Ito F., Shibata S., Takahashi K., Tsujimura A., et al.: “Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma”. Cancer, 2002, 94, 1713.

[14] Tamura R., Kashima K., Asatani M., Nishino K., Nishikawa N., Sekine M., et al.: “Preoperative ultrasound-guided needlebiopsy of 63 uterine tumors having high signal intensity upon T2- weighted magnetic resonance imaging”. Int. J. Gynecol. Cancer, 2014, 24, 1042.